Neoantigen Vaccine Development for Breast Cancer
Neoantigen vaccines represent a cutting-edge approach in the immunotherapy landscape for breast cancer, targeting unique peptides that arise from tumor-specific mutations. Alfa Cytology is at the forefront of neoantigen vaccine development for breast cancer, offering a comprehensive suite of services that encompass the entire vaccine development process.
Introduction to Neoantigen Vaccine
Breast cancer has become the most commonly diagnosed cancer worldwide. Despite advances in chemotherapy, endocrine therapy, and HER2-targeted therapy over the past few decades, breast cancer recurrence and metastasis remain a huge challenge. Cancer vaccines are an attractive option because they are designed to induce long-lasting immune responses to eradicate tumor cells. Neoantigen vaccines are based on epitopes from the antigenic portion of mutated proteins expressed in cancer cells. These highly immunogenic antigens may trigger the immune system to fight cancer cells. There are broadly two types of tumor antigens: tumor-associated antigens (TAA) and tumor-specific antigens (TSA). Neoantigens are a subclass of TSA that are tumor-specific and unique to tumor cells. Over the past few years, neoantigen vaccines have emerged as an emerging immunotherapy due to the cost-effectiveness of sequencing technology.
Fig.1 The main types of neoantigen vaccines. (Peng M, et al., 2019)
Our Services
The research on neoantigen vaccines is an important part of the research on neoantigen targeted therapy, and the production and development of neoantigen vaccines is an important breakthrough in the field of cancer treatment. Alfa Cytology provides the research and development of neoantigen vaccines, including personalized neoantigen vaccines, public neoantigen vaccines, and bispecific antibodies related to public neoantigens. Our neoantigen vaccine has good safety and efficacy.
| Services | Description |
| Personalized neoantigen vaccines | The personalized neoantigen vaccines we provide include DNA vaccines, mRNA vaccines, dendritic vaccines, peptide vaccines and nano vaccines. Our personalized neoantigen vaccines can express multiple neoantigens from patient tumors, generate stronger immune responses, and have high stability and delivery efficiency. |
| Public neoantigen vaccine | Our public neoantigen vaccine can be rapidly applied to cancer patients and could reduce treatment costs, making it an ideal target for cancer treatment. |
| Bispecific antibodies related to public neoantigens | We can assist you in developing bispecific antibodies related to public neoantigens, combining the advantages of neoantigens and bispecific antibodies to help cancer research. |
Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world in BC research. We can provide you with BC neoantigen vaccine development services and help in the development of therapies and diagnostics for BC. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.
Reference
- Peng M, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019 Aug 23;18(1):128.